The primary purpose of this study is to evaluate the efficacy of a new type of exposure- and acceptance-based smoking cessation treatment vs. standard behavioral smoking cessation treatment, in conjunction with the use of the transdermal nicotine patch. In both treatments, participants will receive one 60-minute individual session, seven 2-hour group sessions and two individual brief telephone contacts over an eight-week period. Both treatments include 8 weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after the treatment sessions have ended. Participants will provide follow-up data with regard to their smoking status through a one-year follow-up period.
1. 18-65 years of age, 2. a regular smoker for at least one year, 3. currently smoking 10 or more cigarettes per day, 4. report motivation to quit smoking in the next month.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
116
Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
Butler Hospital
Providence, Rhode Island, United States
Number of Participants With Biochemically Verified Smoking Abstinence
1. Carbon monoxide of expired air 2. Salivary cotinine level of saliva
Time frame: Six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.